Tumor agnostic efficacy of selpercatinib in patients with RET fusion+ solid tumors: A global, multicenter, registrational trial update (LIBRETTO-001). This is an ASCO Meeting Abstract from the 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback